If your patient has commercial insurance through an employer or insurance carrier, your patient may be eligible to use the Corlanor® Copay Card, which may pay up to $160 toward their prescription cost after they pay no more than $20 for each prescription of Corlanor®.
For Eligible Patients with Commercial Insurance: The Corlanor® Tablet Copay Card reduces out-of-pocket (OOP) costs for Corlanor®. Each patient is responsible for up to the first $20 of OOP costs. The Corlanor® Tablet Copay Card may then pay up to $160 per 30-day supply to cover OOP costs for Corlanor® (up to $2,600 per year), including co-payments, co-insurance, and prescription deductible. Your patients may renew their participation in the program every 12 months by going to www.corlanor.com/corlanor-copay-card/ or calling 1-844-6CORLANOR.
Eligibility Criteria for Copay Offer: This offer is valid in the United States. Open to adult patients with a Corlanor® (ivabradine) prescription and commercial insurance for Corlanor®. Patients may not seek reimbursement for value received from the Corlanor® Tablet Copay Card from any third-party payers, including a flexible spending account or healthcare savings account. This program is not open to uninsured patients, cash-paying patients or patients receiving prescription reimbursement under any federal, state, or government funded healthcare program such as Medicare, Medicare Advantage, Medicare Part D, the Retiree Drug Subsidy Program, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD) or TRICARE® or where prohibited by law. Cash Discount Cards and other non-insurance plans are not valid as primary under this offer. If at any time patients begin receiving prescription drug coverage under any such federal, state or government funded healthcare program, patient will no longer be able to use this card and must call
Additional Program Details and Restrictions for Copay Offer: A valid Prescriber ID# is required on the prescription. Program provides OOP assistance for each patient in a 1-year period dating from initial activation. Patient is responsible for costs above the annual maximum. If patients become aware that their health plan or pharmacy benefit manager does not allow the use of manufacturer copay support as part of their health plan design, patients agree to comply with their obligations, if any, to disclose their use of the card to their insurer.
For eligible uninsured or underinsured patients, Corlanor® may be available from the Amgen Safety Net Foundation at no cost.
The Amgen Safety Net Foundation supports uninsured patients and certain underinsured patients who do not have coverage for their Amgen medication and have a financial need. Qualifying uninsured patients must not be eligible for Medicaid, Medicare, or any other financial support options.
Visit www.amgensafetynetfoundation.com or call 1-888-762-6436.
The Corlanor® Copay Card is not available for patients receiving prescription reimbursement under any federal-, state-, or government-funded healthcare programs such as Medicare, Medicare Advantage, Medicare Part D, or Medicaid.
IMPORTANT SAFETY INFORMATION
Corlanor® is contraindicated in patients with acute decompensated heart failure, clinically significant hypotension, sick sinus syndrome, sinoatrial block, 3rd degree atrioventricular block (unless a functioning demand pacemaker is present), clinically significant bradycardia, severe hepatic impairment, pacemaker dependence (heart rate maintained exclusively by the pacemaker), and concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors.
Corlanor® may cause fetal toxicity when administered to a pregnant woman based on embryo-fetal toxicity and cardiac teratogenic effects observed in animal studies. Advise females of reproductive potential to use effective contraception when taking Corlanor®.
Corlanor® increases the risk of atrial fibrillation. The rate of atrial fibrillation in patients treated with Corlanor® compared to placebo was 5% vs. 3.9% per patient-year, respectively. Regularly monitor cardiac rhythm. Discontinue Corlanor® if atrial fibrillation develops.
Bradycardia and Conduction Disturbances
Adult Heart Failure Patients
Bradycardia, sinus arrest and heart block have occurred with Corlanor®. The rate of bradycardia in patients treated with Corlanor® compared to placebo was 6% (2.7% symptomatic; 3.4% asymptomatic) vs. 1.3% per patient-year, respectively. Risk factors for bradycardia include sinus node dysfunction, conduction defects, ventricular dyssynchrony, and use of other negative chronotropes. Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsades de pointes, especially in patients with risk factors such as use of QTc prolonging drugs.
Concurrent use of verapamil or diltiazem also increases Corlanor® exposure, contributes to heart rate lowering, and should be avoided. Avoid use of Corlanor® in patients with 2nd degree atrioventricular block unless a functioning demand pacemaker is present.
Pediatric Heart Failure Patients
Bradycardia and first-degree heart block were observed in pediatric patients treated with Corlanor®. Asymptomatic and symptomatic bradycardia were observed in 6.8% and 4.1% of pediatric patients treated with Corlanor®, respectively. In the placebo treatment arm, 2.4% of pediatric patients had asymptomatic bradycardia, but none had symptomatic bradycardia. Bradycardia was managed through dose titration but did not result in study drug discontinuation.
Adult Heart Failure Patients
The most common adverse drug reactions reported at least 1% more frequently with Corlanor® than placebo and that occurred in more than 1% of patients treated with Corlanor® were bradycardia (10% vs. 2.2%), hypertension or increased blood pressure (8.9% vs. 7.8%), atrial fibrillation (8.3% vs. 6.6%), and luminous phenomena (phosphenes) or visual brightness (2.8% vs. 0.5%).
In postmarketing experience, torsades de pointes has been observed.
Pediatric Heart Failure Patients
Bradycardia (symptomatic and asymptomatic) occurred at rates similar to those in adults. Phosphenes were observed in pediatric patients treated with Corlanor®.
Heart Failure in Adult Patients
Corlanor® is indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use.
Heart Failure in Pediatric Patients
Corlanor® is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate.